Skip to main content

Mainz Biomed B.V. (MYNZ)

NASDAQ: MYNZ · Delayed Price · USD
9.78
-0.07 (-0.71%)
At close: Nov 29, 2021 4:00 PM
10.76
0.98 (10.02%)
Pre-market:Nov 30, 2021 6:28 AM EST
Market Cap114.52M
Revenue (ttm)744,175
Net Income (ttm)-813,389
Shares Out11.71M
EPS (ttm)-0.07
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume126,844
Open10.10
Previous Close9.85
Day's Range9.50 - 10.35
52-Week Range8.25 - 18.00
Betan/a
Analystsn/a
Price Targetn/a
Earnings Daten/a

About MYNZ

Mainz Biomed is a molecular genetics cancer diagnostic company formed in 2021 to acquire PharmGenomics with the purpose of commercializing their product portfolio in Europe and the United States. PharmGenomics, a German DIN EN ISO 13485-certified manufacturer of in-vitro diagnostic (“IVD”) tests with its own molecular genetic laboratory, has developed several IVD tests for the European market since it was founded in 2008. Our portfolio consists of the following products and product candidates: ColoAlert, a colorectal cancer screening stool ...

IndustryDiagnostics & Research
IPO DateNov 5, 2021
CEOGuido Baechler
Employees12
Stock ExchangeNASDAQ
Ticker SymbolMYNZ
Full Company Profile

Financial Performance

In 2020, MYNZ's revenue was $493,565, an increase of 75.40% compared to the previous year's $281,393. Losses were -$586,895, -38.68% less than in 2019.

Financial Statements

News

Mainz Biomed Establishes Partnership with Precision for Medicine to Support ColoAlert's U.S. Regulatory and Commercia...

BERKELEY, Calif. and MAINZ, Germany, Nov. 30, 2021 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostics company specializing in the ear...

4 hours ago - GlobeNewsWire

Mainz Biomed Appoints Dr. Soren Thestrup-Nielsen M.D. to Strategic Advisory Board

BERKELEY, Calif. and MAINZ, Germany, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the earl...

1 week ago - GlobeNewsWire

Mainz Biomed to Exhibit ColoAlert at MEDICA 2021, the World's Largest Medical Trade Fair

BERKELEY, Calif. and MAINZ, Germany, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the earl...

2 weeks ago - GlobeNewsWire

Mainz Biomed Appoints Former Roche Division President Heiner Dreismann to Strategic Advisory Board

BERKELEY, Calif. and MAINZ, Germany, Nov. 11, 2021 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the earl...

2 weeks ago - GlobeNewsWire

Mainz Biomed Announces Exercise of Over-Allotment Option

BERKELEY, Calif. and MAINZ, Germany, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the earl...

3 weeks ago - GlobeNewsWire

Mainz Biomed Commences Trading on Nasdaq Under Ticker Symbol ‘MYNZ'

BERKELEY, Calif. and MAINZ, Germany, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the earl...

3 weeks ago - GlobeNewsWire

MYNZ Closes Its First Day of Trading on the Nasdaq Capital Market

BERKELEY, Calif. and MAINZ, Germany, Nov. 05, 2021 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostics company specializing in the ear...

3 weeks ago - GlobeNewsWire

MYNZ Shares Have Commenced Trading on the Nasdaq Capital Market

BERKELEY, Calif. and MAINZ, Germany, Nov. 05, 2021 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (Nasdaq:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostics company specializing in the ear...

3 weeks ago - GlobeNewsWire

Mainz Biomed N.V. Announces Pricing of Initial Public Offering

BERKELEY, Calif. and MAINZ, Germany, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostics company specializing in the ear...

3 weeks ago - GlobeNewsWire

German micro-cap Mainz Biomed files and sets terms for a $10 million US IPO

Mainz Biomed, which is commercializing in vitro molecular tests for cancer screening, filed on Tuesday with the SEC to raise up to $10 million in an initial public offering.

1 month ago - Renaissance Capital

Mainz Biomed IPO Registration Document (F-1)

Mainz Biomed B.V. has filed to go public with an IPO on the NASDAQ.

1 month ago - SEC